Form 4: RXRX CSO Hallett Reports RSU Vesting, Tax Withholding

Recursion Pharmaceuticals' Chief Scientific Officer, David Hallett, reported the acquisition of over 526,000 shares through RSU vesting and the disposition of 11,400 shares for tax purposes.

Summary

• David Hallett, Chief Scientific Officer of Recursion Pharmaceuticals, Inc. (RXRX), reported transactions on February 6, 2026.
• Acquired 502,064 shares of Class A Common Stock through a Restricted Stock Unit (RSU) grant, vesting as one-sixteenth (1/16th) of the units every three months starting May 15, 2026.
• Acquired an additional 24,254 shares of Class A Common Stock through an RSU grant that vested immediately upon the grant date.
• Disposed of 11,400 shares of Class A Common Stock at a price of $3.98 per share to satisfy tax withholding obligations related to the net settlement of restricted stock units.
• Following these transactions, Hallett beneficially owns 1,109,059 shares of Class A Common Stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects ongoing executive equity compensation and retention, which is generally favorable for aligning management and shareholder interests, despite the routine tax-related disposition.

Positives

• Acquisition of 526,318 shares (502,064 + 24,254) through RSU grants indicates continued equity compensation and alignment of executive interests with shareholders.
• The immediate vesting of 24,254 shares provides immediate equity ownership.

Negatives

• Disposition of 11,400 shares for tax withholding, though a standard practice, reduces the direct shareholding.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that RSU grants and subsequent tax-related dispositions are standard practices in executive compensation across the biotechnology and pharmaceutical sectors. These transactions reflect the ongoing compensation structure for key executives like a Chief Scientific Officer, aligning their long-term incentives with company performance, particularly in a growth-oriented firm like Recursion Pharmaceuticals.

Stakeholder Impact

• Shareholders: The RSU grants align the Chief Scientific Officer's interests with shareholders, potentially encouraging long-term value creation. The tax-related disposition is a minor, routine event.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• Further vesting of the 502,064 RSUs will occur quarterly, with the next vesting date on May 15, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU grants and tax-related share dispositions). While the grants align executive interests with shareholders, these transactions are standard and do not present new information that would fundamentally alter the investment thesis for Recursion Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate as the filing does not provide a strong catalyst for either buying or selling the stock.

Keywords

Recursion Pharmaceuticals, RXRX, David Hallett, Chief Scientific Officer, Form 4, Insider Trading, RSU, Restricted Stock Units, Equity Compensation, Stock Vesting, Tax Withholding